Zetia Gains Hyperlipidemia Treatment Indication In Combination With Fenofibrate
This article was originally published in The Pink Sheet Daily
Schering/Merck’s latest indication for ezetimibe does not reference an increase in HDL cholesterol.
You may also be interested in...
A Phase III trial testing dapagliflozin in chronic kidney disease patients with and without diabetes was stopped early following a recommendation from an independent data monitoring committee.
The company is the latest big pharma to announce clinical trial delays due to the COVID-19 pandemic and has postponed an R&D day, but it also delivered the message that supply and commercial operations appear on track.
Biogen confirmed that some patients treated with Spinraza are temporarily having their dosing postponed as hospital systems brace for COVID-19, potentially a broader issue for the industry.